PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-848.38
Negative P/E while Drug Manufacturers - Specialty & Generic median is 1.55. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
124.39
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.49. Jim Chanos would check for potential asset write-down risks.
382.57
P/FCF of 382.57 versus zero FCF in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify cash flow quality.
382.57
P/OCF of 382.57 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
124.39
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.50. Jim Chanos would check for valuation bubble risks.
-0.03%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is 0.52%. Seth Klarman would investigate path to profitability.
0.26%
FCF yield of 0.26% versus zero FCF in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify cash flow quality.